Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines
Brief Summary: This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.


Options:
A: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month
B: Arm Label: Cervarix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil
C: Arm Label: Cervarix 1/Placebo Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 1/Placebo/Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2/Placebo/Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2 Group, Cervarix 2/Placebo/Cervarix 2 Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2/Placebo/Cervarix 2 Group
D: Arm Label: Girls 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Boys 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls and Boys 9 to 14 Years V503 at Months 0 and 12; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls 9 to 14 Years V503 at Months 0, 2, and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Young Women 16 to 26 Years V503 at Months 0, 2, and 6; Type: ACTIVE_COMPARATOR; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Intervention Type: BIOLOGICAL; Name: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine); Assigned to Arm(s): Boys 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0, 2, and 6, Girls and Boys 9 to 14 Years V503 at Months 0 and 12, Young Women 16 to 26 Years V503 at Months 0, 2, and 6

Answer: B